Loading clinical trials...
Loading clinical trials...
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Conditions
Interventions
vobramitamab duocarmazine
Locations
21
United States
UCLA Department of Medicine - Hematology/Oncology
Santa Monica, California, United States
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
The Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland, United States
START Midwest
Grand Rapids, Michigan, United States
Nebraska Methodist Hospital
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Start Date
November 21, 2018
Primary Completion Date
March 18, 2023
Completion Date
March 18, 2023
Last Updated
July 31, 2025
NCT03340506
NCT05969860
NCT06681064
NCT04693377
NCT04895709
NCT05005403
Lead Sponsor
MacroGenics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions